EMERGENCE OF FLUOROQUINOLONE-RESISTANT ESCHERICHIA-COLI AT A CANCER CENTER

被引:164
作者
KERN, WV
ANDRIOF, E
OETHINGER, M
KERN, P
HACKER, J
MARRE, R
机构
[1] UNIV HOSP & MED CTR ULM,INFECT DIS & CLIN IMMUNOL SECT,D-89070 ULM,GERMANY
[2] UNIV WURZBURG,THEODOR BOVERI INST BIOSCI,D-97070 WURZBURG,GERMANY
[3] UNIV HOSP & MED CTR ULM,DEPT HEMATOL ONCOL,D-89070 ULM,GERMANY
[4] UNIV HOSP & MED CTR ULM,DEPT BACTERIOL,D-89070 ULM,GERMANY
关键词
D O I
10.1128/AAC.38.4.681
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Prophylactic treatment with fluoroquinolones of patients with profound neutropenia has been found to be useful for preventing gram-negative bacteremia and has become a standard preventive-therapy strategy in many cancer centers, but the development of bacterial resistance is a cause of concern. During the past few years, we have observed an increasing number of patients with leukemia from whom fluoroquinolone-resistant strains of Escherichia coli were isolated. The increase was significant in this patient population, and among patients with other underlying diseases, the rates of isolation of such strains per number of discharges were significantly lower and did not increase. Most of the leukemia case patients (16 of 19) had been pretreated with an oral quinolone (ofloxacin), with cumulative doses until the first isolation of a resistant E. coli strain ranging from 0 to 97.8 g (median, 14.4 g). Repeated isolation of such strains was seen in 8 of 17 patients during a follow-up period of greater-than-or-equal-to 4 weeks and in 1 of 6 patients during a follow-up period of greater-than-or-equal-to 16 weeks. Ten patients developed bacteremia (mortality, 1 of 10). On the basis of the number of patients with leukemia admitted to the hematology-oncology service, the incidence of bacteremia caused by fluoroquinolone-resistant E. coli increased from <0.5% in 1988-1989 and 0.8% in 1990-1991 to 4.5% in 1992-1993 (P < 0.01). MICs for nine isolates obtained from cultures of blood from different patients ranged between 8 and 16 mug/ml (ciprofloxacin and PD 131628), 8 and 32 mug/ml (ofloxacin and BAY Y 3118), and 16 and 32 mug/ml (sparfloxacin) and indicated resistance to trimethoprim-sulfamethoxazole, ampicillin, doxycycline, and chloramphenicol. Of nine isolates obtained from cultures of blood from different patients and that were subjected to genomic DNA typing by pulsed-field gel electrophoresis of XbaI digests, seven were typeable. Among these, four different genotypes were identified, suggesting both the independent development and the horizontal spread of resistant clones of E. coli.
引用
收藏
页码:681 / 687
页数:7
相关论文
共 59 条
[1]   CLINICAL ISOLATE OF CITROBACTER-FREUNDII HIGHLY RESISTANT TO NEW QUINOLONES [J].
AOYAMA, H ;
FUJIMAKI, K ;
SATO, K ;
FUJII, T ;
INOUE, M ;
HIRAI, K ;
MITSUHASHI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (06) :922-924
[2]   NORFLOXACIN RESISTANCE IN A CLINICAL ISOLATE OF ESCHERICHIA-COLI [J].
AOYAMA, H ;
SATO, K ;
KATO, T ;
HIRAI, K ;
MITSUHASHI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) :1640-1641
[3]  
ARDUINO S, 1992, 32ND INT C ANT AG CH
[4]   INFECTION PROPHYLAXIS IN NEUTROPENIC PATIENTS WITH ACUTE-LEUKEMIA - A RANDOMIZED, COMPARATIVE-STUDY WITH OFLOXACIN, CIPROFLOXACIN AND COTRIMOXAZOLE COLISTIN [J].
ARNING, M ;
WOLF, HH ;
AUL, C ;
HEYLL, A ;
SCHARF, RE ;
SCHNEIDER, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 :137-142
[5]  
CARRATALA J, 1992, 32ND INT C ANT AG CH
[6]  
CHIDA T, 1984, CHEMOTHERAPY TOKY S1, V32, P109
[7]   CROSS-RESISTANCE TO FLUOROQUINOLONES IN MULTIPLE-ANTIBIOTIC-RESISTANT (MAR) ESCHERICHIA-COLI SELECTED BY TETRACYCLINE OR CHLORAMPHENICOL - DECREASED DRUG ACCUMULATION ASSOCIATED WITH MEMBRANE-CHANGES IN ADDITION TO OMPF REDUCTION [J].
COHEN, SP ;
MCMURRY, LM ;
HOOPER, DC ;
WOLFSON, JS ;
LEVY, SB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1318-1325
[8]   PROPHYLACTIC CO-TRIMOXAZOLE VERSUS NORFLOXACIN IN NEUTROPENIC CHILDREN - PERSPECTIVE RANDOMIZED STUDY [J].
CRUCIANI, M ;
CONCIA, E ;
NAVARRA, A ;
PERVERSI, L ;
BONETTI, F ;
ARICO, M ;
NESPOLI, L .
INFECTION, 1989, 17 (02) :65-69
[9]  
DANTONIO D, 1991, CURR THER RES CLIN E, V50, P304
[10]   INFECTION PROPHYLAXIS IN ACUTE-LEUKEMIA - A COMPARISON OF CIPROFLOXACIN WITH TRIMETHOPRIM-SULFAMETHOXAZOLE AND COLISTIN [J].
DEKKER, AW ;
ROZENBERGARSKA, M ;
VERHOEF, J .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (01) :7-12